Primary biliary cholangitis (PBC) experts Thomas Berg, Michael Trauner, and Palak Trivedi discuss the current unmet needs in PBC management, the data behind the recent approval of PPAR agonists elafibranor and seladelpar, and the paradigm changes that they anticipate these drugs will bring to the field.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


